{"transactions":[{"id":2729230,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":3797921,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":438098},"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}},{"id":2729229,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":11428570,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1318311},"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}},{"id":2729228,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2020-12-23","kind":"purchase","acquired":true,"shares":3797921,"price":0.9214,"value":3499404.4094,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":3797921,"derivative":{"underlying":"Common Stock","underlying_shares":438098},"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}},{"id":2729227,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":2068909,"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}},{"id":2729226,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":438098,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":1756409,"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}},{"id":2729225,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139733,"kind":"person","name":"Asanuma Sakae","position":1,"cik":"0001857822","reported_name":"Asanuma Sakae","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:20.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1318311,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC."}],"balance_after":1318311,"source":{"system":"sec-edgar","filing":"0000899243-21-018116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018116/doc4.xml","form_type":"4"}}]}